PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

• M. Hamadani,
• C. N. Graham,
• L. Liao,
• K. H. Zhang,
• H. Strat,
• D. Ungar,
• W. Ai,
• L. Chen,
• C. Carlo-Stella

Affiliations

M. Hamadani

1 Medical College of Wisconsin, Milwaukee

C. N. Graham

2 RTI International, Research Triangle Park

L. Liao

3 ADC Therapeutics America, Inc

K. H. Zhang

2 RTI International, Research Triangle Park

H. Strat

2 RTI International, Research Triangle Park

D. Ungar

4 ADC Therapeutics America, Inc., Murray Hill

W. Ai

5 Division of Hem/Onc, University of California, San Francisco, United States of America

L. Chen

4 ADC Therapeutics America, Inc., Murray Hill

C. Carlo-Stella

6 Humanitas Clinical and Research Center – IRCCS, and Humanitas University, Milan, Italy